Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Vertex stock price target cut to $533 by Piper Sandler
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
Victoria News3d
Vancouver Island girl off to Disney World thanks to Help Fill a Dream
The Milligans were sent off on their trip by Georgia Strait Towing, which helps volunteer and fundraise for Help Fill a Dream ...
nzcity.co.nz5d
Cystic Fibrosis NZ say funding the drug Trikafta for young children would be a smart decision for Pharmac
Its Respiratory Advisory Committee has recommended funding with high priority for children aged two to five years. The medicine is currently only funded for ages six and up Cystic Fibrosis NZ CEO Lisa ...
Royalty Pharma’s Internalization and Promising Catalysts Lead to Buy Rating with Attractive Valuation
Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research Report) and increased the ...
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Healio6d
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...